Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New needle technique may spare breast cancer patients from surgery

NCT ID NCT04107636

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a special needle device (vacuum-assisted biopsy) can completely remove small breast cancers using ultrasound guidance, instead of traditional surgery. 45 women with small, early-stage breast cancers participated. The goal was to see if this less invasive method could successfully remove the entire tumor, which might mean fewer side effects and faster recovery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

45 people

The number who actually took part.

Started

Aug 2021

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female sex. * 18 years or older. * US visible breast cancer. * Histologically proven non-lobular invasive breast carcinoma with maximum diameter of 15 mm as assessed by US. * Willing and able to undergo preoperative breast MRI * Able to fill out the questionnaire * Able to provide informed consent. Exclusion Criteria: * Male sex. * 17 years or younger. * No proven invasive breast cancer. * Poor US visibility of the breast cancer. * Neoadjuvant therapy. * Contra-indications to breast MRI or intravenous contrast administration. * Unable to fill out the questionnaire * Unable to provide informed consent. * Patients with breast implants. * Pregnancy. * Presence of additional malignant lesions at ipsilateral site on MRI.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Radboudumc

    Nijmegen, Gelderland, 6500 HB, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.